💊
Jemperli
dostarlimab
Endometrial Neoplasms
✅ Authorised
✅
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Jemperli is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.
⚠️ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli